Non-Engineered Physiologically Modulated Nanovesicles Augment Antitumor Immune Responses via Dual-Pathway T Cell Activation.

Key Points

• This research aims to investigate the effectiveness of a non-engineered nanovaccine in enhancing antitumor immune responses through dual-pathway T cell activation.
• Utilized non-engineered, physiologically modulated nanovesicles as vaccines.
• Assessed dual-pathway T cell activation mechanisms through both antigen self-presentation and dendritic cell-mediated activation.
• Evaluated broad-spectrum antitumor activity and immune memory against tumor recurrence.
• The ASCENT nanovaccine induced robust immune responses, leading to significant tumor suppression.
• The immune memory generated was durable, effectively preventing tumor recurrence and metastasis.